Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?
Therapeutic Advances in Infectious Disease · 2026-10 · 13
DOI: 10.1177/20499361261503133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Infectious Disease, online erschienen am 27.10.2026. Verfasst von Reem Elajez und 7 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation- Medical research center, Qatar National Library.
Abstract (Originalsprache)
Background
Aminoglycosides are widely used in dual antipseudomonal therapy for acute pulmonary exacerbations in cystic fibrosis (CF). Due to altered pharmacokinetics in CF, achieving recommended pharmacokinetic/pharmacodynamic (PK/PD) targets is challenging and the impact of target attainment on clinical outcomes remains unclear.
Objectives
To evaluate whether currently recommended aminoglycoside dosing regimens in CF achieve PK/PD targets in clinical practice, and whether target attainment correlates with clinical improvements in CF patients. Design/methods A two-year, single-center cohort study was conducted in adult CF patients receiving aminoglycoside during acute exacerbation. Aminoglycoside levels were obtained to estimate PK parameters. Clinical symptoms and pulmonary function were assessed at admission (baseline) and discharge.
Results
Fourteen treatment courses were analyzed among nine patients. Amikacin (n=10, mean dose 30.9 ± 2 mg/kg), or gentamicin (n=4, mean dose 10.5 ± 0.7 mg/kg) were administered. The target C max :MIC ratio of 8-10 was achieved in 50% of amikacin courses and none of the gentamicin courses. Most patients improved clinically, evident by symptoms’ resolution and increased ppFEV 1 . Target attainment was associated with a numerically greater ppFEV 1 improvement, though not statistically significant (P=0.29).
Conclusions
The pre-defined PK/PD target was attained in less than half of the cases treated, underscoring the need for optimized dosing strategies. Nonetheless, clinical improvement occurred regardless of target attainment. This highlights the need of larger randomized controlled studies to define the relationship between aminoglycoside PK/PD target achievement and clinical outcomes among CF patients.
Förderung
- Hamad Medical Corporation- Medical research center
- Qatar National Library
Zitieren
APA
Elajez, R., Bakdach, D., Hussein, M., Elarabi, A., Mohammad, A., Al-Adab, A., Al-Langawi, M., & Thomas, M. (2026). Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?. Therapeutic Advances in Infectious Disease, 13. https://doi.org/10.1177/20499361261503133
Vancouver
Elajez R, Bakdach D, Hussein M, Elarabi A, Mohammad A, Al-Adab A, et al. Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?. Therapeutic Advances in Infectious Disease. 2026;13. doi:10.1177/20499361261503133
BibTeX
@article{Elajez2026,
author = {Elajez, Reem and Bakdach, Dana and Hussein, Mousa and Elarabi, Anam and Mohammad, Abdullah and Al-Adab, Aisha and Al-Langawi, Mona and Thomas, Merlin},
title = {Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?},
journal = {Therapeutic Advances in Infectious Disease},
year = {2026},
volume = {13},
doi = {10.1177/20499361261503133}
}
EUVIMED